Summary
Survival and disease-free benefits of chemotherapy for colon cancer disappears after 10 years, according to Dr. Roy E. Smith and his colleagues of the NSABP in Pittsburgh. The immunotherapy regimen was not disease-free, although there was a better survival rate with conditions other than colon cancer.
Previously, chemotherapy after surgery indicated a 5 year disease-free and overall improved survival rate than surgery alone. Since that kind of chemotherapy and immunotherapy is no longer used, Dr. Jean Grem of the University of Nebraska Medical Center in Omaha recommends testing new agents, using 3-year disease-free survival measurements instead of 5-year survival.
Original source:
http://www.sciencedaily.com/releases/2004/08/040804084854.htm
Details
-
In 1988, a team of researchers reported that, for patients with colon cancer, postoperative chemotherapy was associated with better 5-year disease-free and overall survival than surgery alone.
- However, this survival benefit disappeared after 10 years, according to an update of that same clinical trial that appears in the August 4 issue of the Journal of the National Cancer Institute.
- In 1977, the National Surgical Adjuvant Breast and Bowel Project (NSABP) began a randomized clinical trial, NSABP protocol C-01, to evaluate the efficacy of adjuvant chemotherapy or postoperative immunotherapy after surgery compared with surgery alone in colon cancer patients.
- This improvement was associated with fewer deaths from conditions other than colon cancer among the older patients in the trial.
- It should be noted, however, that because the chemotherapy and immunotherapy used in this trial are no longer recommended for colon cancer, it is possible that the newer chemotherapy regimens would be better than surgery alone, the authors write.
- In an editorial, Jean Grem, M.D., of the University of Nebraska Medical Center in Omaha, notes that neither of the regimens tested in this trial are currently in clinical use, so there is a need to find appropriate surrogate end points for colon cancer trials to expedite the clinical testing phase of potential new agents.
- She suggests the possibility of using 3-year disease-free survival as a surrogate end point for 5-year overall survival, noting that its advantages include "allowing more timely completion of trials, and more rapid implementation of new trials testing promising new therapies."
About the author: Mike Adams is an award-winning journalist and holistic nutritionist with a mission to teach personal and planetary health to the public He has authored and published thousands of articles, interviews, consumers guides, and books on topics like health and the environment, and he has authored and published several downloadable personal preparedness courses including a downloadable course focused on safety and self defense. Adams is an honest, independent journalist and accepts no money or commissions on the third-party products he writes about or the companies he promotes. In mid 2010, Adams produced TV.NaturalNews.com, a natural health video sharing website offering user-generated videos on nutrition, green living, fitness and more. He's also the CEO of a highly successful email newsletter software company that develops software used to send permission email campaigns to subscribers. Adams is currently the executive director of the Consumer Wellness Center, a 501(c)3 non-profit, and regularly pursues cycling, nature photography, Capoeira and Pilates. He's also author a large number of health books offered by Truth Publishing and is the creator of numerous reference website including NaturalPedia.com and the free downloadable Honest Food Guide. His websites also include the free reference sites HerbReference.com and HealingFoodReference.com. Adams believes in free speech, free access to nutritional supplements and the innate healing ability of the human body. Known by his callsign, the 'Health Ranger,' Adams posts his missions statements, health statistics and health photos at www.HealthRanger.org
Have comments on this article? Post them here:
people have commented on this article.
Thursday, August 19, 2004
Email this article to a friend
Share
this article on: 
